Policy / Regulatory

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
NHC (NHFPC)NMPA

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures
NHSA (prev. SMIA)

NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures

China's NHC Announces Initiative to Boost Gerontology Medical Services
NHC (NHFPC)

China’s NHC Announces Initiative to Boost Gerontology Medical Services

NMPA Draft Proposal Aims to Strengthen Supervision of Drug Entrusted Manufacturing
NMPA

NMPA Draft Proposal Aims to Strengthen Supervision of Drug Entrusted Manufacturing

China's NMPA Issues Guidelines for Domestic Manufacturing of Imported Medical Devices
NMPA

China’s NMPA Issues Guidelines for Domestic Manufacturing of Imported Medical Devices

Show More